Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-09-21

Schrödinger, Inc.

Schrödinger sells physics-based molecular discovery software to life science and materials customers and uses the same platform in partnered and proprietary drug programs.

ai biotech cloud healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Modeling Tool to Discovery Control Layer

The five-year upside depends less on a miracle drug and more on whether hosted delivery and agentic software turn a respected scientific engine into a broader workflow tollbooth. The stock can still work from here, but the next proof points are commercial rather than scientific.

Analysis

Thesis

Over five years, Schrödinger can compound value by turning respected molecular modeling tools into a governed discovery operating layer: hosted delivery, LiveDesign, Bunsen, and selective partner or spinout economics can lift revenue quality and wallet share faster than reported seats imply, without needing a single blockbuster internal drug.

Last Economy Alignment

Cheaper cognition should expand discovery throughput and user count, and Schrödinger owns validated workflow software with real switching friction rather than selling pure human labor. But it does not control the deepest compute or proprietary data rails, so open tools and in-house pharma agents can still cap value capture.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

The upside is mainly a business-model upgrade. If hosted contracts make revenue more recurring, Bunsen and LiveDesign spread usage beyond specialist modelers, and spinout or partner structures keep pipeline upside without funding all of it on balance sheet, the market can value the company as a stickier software-control layer with selective biotech optionality.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is economic capture, not scientific relevance. Schrödinger likely remains useful, but the equity case weakens if Bunsen expands activity without moving the company into a higher-value workflow-control budget, if hosted transition noise lasts longer than expected, or if cash burn limits how much upside the company can self-fund before partner or capital-market support is needed.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new SEC filing or operating KPI emerged between September 12 and September 21, 2026; Q3 remains the next real proof point.
The September 14, 2026 Morgan Stanley conference appearance did not come with a public reset to guidance, capital plans, or hosted-transition targets.
The stock stayed near its 52-week high into September 18-21, 2026, which raises the burden on the next ACV and hosted-mix readout.

Thesis update

No core thesis change. The September 9, 2026 Tectora transaction modestly strengthens the case that Schrödinger can externalize capital-heavy pipeline spend while keeping software, milestone, and royalty upside.

Forecast update

Upside per share is less open-ended because the stock has already rerated on better software sentiment before the next proof points on Bunsen monetization and hosted economics.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.40

They own trusted software that helps drug teams plan, run, and verify molecular design work, so cheaper AI can increase usage instead of erasing demand. The risk is that large pharma keeps the data and orchestration layer in-house, leaving Schrödinger as a useful tool rather than the control point.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$21.43

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research